From:  A survey of the composition, safety, efficacy and regulation of non-autologous biologic treatments in human musculoskeletal pathologies

 Therapeutic outcomes for treating COVID-19 ARDS patients with a bone marrow MSC derived exosome product [40]

Patient cohortAll-cause mortality
Exosome treated (%)Placebo (%)
All COVID-related ARDS29.447.1
Moderate to severe ARDS30.872.7

ARDS: acute respiratory distress syndrome; MSC: mesenchymal stromal cell